Table III.
30-d outcomes
| Unmatched patients |
P value | Propensity score-matched patients |
P value | |||
|---|---|---|---|---|---|---|
| SARS-CoV-2 positive patients n = 161 | SARS-CoV-2 negative patients n = 342 | SARS-CoV-2 positive patients n = 123 | SARS-CoV-2 negative patients n = 196 | |||
| 30-d postoperative mortality | ||||||
| 30-d follow-up–no (%) | <.001 | <.001 | ||||
| Alive at hospital | 26 (16.1) | 25 (7.3) | 21 (17.1) | 13 (6.6) | ||
| Alive at rehabilitation | 35 (21.7) | 21 (6.1) | 25 (20.3) | 16 (8.2) | ||
| Alive at home | 74 (46.0) | 282 (82.5) | 62 (50.4) | 158 (80.6) | ||
| Deceased | 26 (16.2) | 14 (4.1) | 15 (12.2) | 9 (4.6) | ||
| 30-d postoperative complications | ||||||
| Number of complications per patient, median (IQR) | 1 (0–3) | 0 (0–1) | <.0001 | 1 (0–2) | 0 (0–1) | <.001 |
| Comprehensive complication index, median (IQR) | 20.9 (0–42.7) | 0 (0–20.9) | <.0001 | 20.9 (0–39.5) | 0 (0–12.2) | <.0001 |
| Pulmonary complications–no (%) | 39 (24.2) | 11 (3.2) | <.0001 | 25 (20.3) | 6 (3.1) | <.0001 |
| Thromboembolic complications–no (%) | 11 (6.8) | 1 (0.3) | <.0001 | 8 (6.5) | 1 (0.5) | .004 |
| Hemorrhagic complications– no (%) | 22 (13.6) | 28 (8.2) | .052 | 16 (9.9) | 20 (10.2) | .49 |
| Infectious complications–no (%) | 13 (8.1) | 27 (7.8) | .97 | 11 (8.9) | 12 (6.1) | .42 |